Evidence map›Paper›PMID 39078710›Full record

ArticleJCI insight2024

Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions.

Yenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, Kritika Bhalla, Alexia Mahy, Roeland Vanhoutte, Sandra Meulemans, Edoardo Cavani, Aleksandar Antanasijevic, Irma Lemmens and 12 more

Abstract readCase Reports
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yenthe MonnensLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Anastasia TheodoropoulouLaboratory for Biomolecular Modeling, Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Karen RosierLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Kritika BhallaLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Alexia MahyLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Roeland VanhoutteLaboratory for Chemical Biology, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Sandra MeulemansLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Edoardo CavaniLaboratory for Biomolecular Modeling, Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Aleksandar AntanasijevicGlobal Health Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Irma LemmensVIB-UGent Center for Medical Biotechnology, Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Jennifer A LeeGreenwood Genetic Center, South Carolina, USA.
Catherine J SpellicyGreenwood Genetic Center, South Carolina, USA.
Richard J SchroerGreenwood Genetic Center, South Carolina, USA.
Ricardo A MaselliDepartment of Neurology, UCD, Sacramento, California, USA.
Chamindra G LavertyDepartment of Neuroscience, UCSD, San Diego, California, USA.
Patrizia AgostinisLaboratory for Cell death Research & Therapy, VIB, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
David J PagliariniDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Steven VerhelstLaboratory for Chemical Biology, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Maria J MarcaidaLaboratory for Biomolecular Modeling, Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Anne RochtusUZ Leuven University Hospital, Leuven, Belgium.
Matteo Dal PeraroLaboratory for Biomolecular Modeling, Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
John Wm CreemersLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Funding

Systems-to-structure approaches for defining mitochondrial protein functionR35GM131795 · NIGMS · WASHINGTON UNIVERSITY · PI David J Pagliarini · 2019 to 2026
$4.8M
NIGMS NIH HHS R35 GM131795
6 · The paper itself

Abstract

Congenital myasthenic syndrome-22 (CMS22, OMIM 616224) is a rare genetic disorder caused by deleterious genetic variation in the prolyl endopeptidase-like (PREPL) gene. Previous reports have described patients with deletions and nonsense variants in PREPL, but nothing is known about the effect of missense variants in the pathology of CMS22. In this study, we have functionally characterized missense variants in PREPL from 3 patients with CMS22, all with hallmark phenotypes. Biochemical evaluation revealed that these missense variants do not impair hydrolase activity, thereby challenging the conventional diagnostic criteria and disease mechanism. Structural analysis showed that the variants affect regions most likely involved in intraprotein or protein-protein interactions. Indeed, binding to a selected group of known interactors was differentially reduced for the 3 variants. The importance of nonhydrolytic functions of PREPL was investigated in catalytically inactive PREPL p.Ser559Ala cell lines, which showed that hydrolytic activity of PREPL is needed for normal mitochondrial function but not for regulating AP1-mediated transport in the transgolgi network. In conclusion, these studies showed that CMS22 can be caused not only by deletion and truncation of PREPL but also by missense variants that do not necessarily result in a loss of hydrolytic activity of PREPL.

Indexed as

Mutation, MissenseMyasthenic Syndromes, CongenitalProlyl OligopeptidasesFemaleHumansMaleMitochondriaPhenotypeSerine EndopeptidasesPREPL protein, humanProlyl OligopeptidasesSerine EndopeptidasesEndocrinologyGeneticsGenetic variation

Identifiers

PMID39078710
PMCPMC11385081

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.